1. Home
  2. GH vs KBH Comparison

GH vs KBH Comparison

Compare GH & KBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GH
  • KBH
  • Stock Information
  • Founded
  • GH 2011
  • KBH 1957
  • Country
  • GH United States
  • KBH United States
  • Employees
  • GH N/A
  • KBH N/A
  • Industry
  • GH Medical Specialities
  • KBH Homebuilding
  • Sector
  • GH Health Care
  • KBH Consumer Discretionary
  • Exchange
  • GH Nasdaq
  • KBH Nasdaq
  • Market Cap
  • GH 4.9B
  • KBH 4.6B
  • IPO Year
  • GH 2018
  • KBH 1987
  • Fundamental
  • Price
  • GH $65.46
  • KBH $61.96
  • Analyst Decision
  • GH Strong Buy
  • KBH Hold
  • Analyst Count
  • GH 22
  • KBH 13
  • Target Price
  • GH $64.91
  • KBH $65.33
  • AVG Volume (30 Days)
  • GH 2.2M
  • KBH 1.4M
  • Earning Date
  • GH 10-29-2025
  • KBH 09-24-2025
  • Dividend Yield
  • GH N/A
  • KBH 1.62%
  • EPS Growth
  • GH N/A
  • KBH N/A
  • EPS
  • GH N/A
  • KBH 7.17
  • Revenue
  • GH $828,849,000.00
  • KBH $6,541,735,000.00
  • Revenue This Year
  • GH $28.30
  • KBH N/A
  • Revenue Next Year
  • GH $22.98
  • KBH N/A
  • P/E Ratio
  • GH N/A
  • KBH $8.63
  • Revenue Growth
  • GH 28.74
  • KBH N/A
  • 52 Week Low
  • GH $20.14
  • KBH $48.90
  • 52 Week High
  • GH $68.23
  • KBH $85.92
  • Technical
  • Relative Strength Index (RSI)
  • GH 59.00
  • KBH 49.50
  • Support Level
  • GH $61.00
  • KBH $60.34
  • Resistance Level
  • GH $68.22
  • KBH $62.41
  • Average True Range (ATR)
  • GH 2.50
  • KBH 1.82
  • MACD
  • GH 0.12
  • KBH -0.09
  • Stochastic Oscillator
  • GH 64.47
  • KBH 53.43

About GH Guardant Health Inc.

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

About KBH KB Home

KB Home is an American construction company that focuses on residential construction in the United States. The company builds single-family homes and communities across different geographical segments which include the West Coast which also derives the majority of the revenue, Southwest, Central, and Southeast. The company operates in several markets and focuses on first-time and move-up homebuyers. It also invests in land acquisition and development to support future building activities and is also engaged in financial services operations which includes providing mortgage banking services through its joint venture with a third party.

Share on Social Networks: